Publication Name	World Journal of Hepatology
Manuscript ID	68617
Country	Italy

Received	2021-05-28 21:01
Peer-Review Started	2021-05-28 21:04
To Make the First Decision
Return for Revision	2021-07-06 01:57
Revised	2021-07-15 16:24
Second Decision	2021-08-11 03:25
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2021-08-11 06:48
Articles in Press	2021-08-11 06:48
Publication Fee Transferred
Edit the Manuscript by Language Editor	2021-08-24 04:29
Typeset the Manuscript	2021-09-17 02:59
Publish the Manuscript Online	2021-09-22 08:09

ISSN	1948-5182 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Opinion Review
Article Title	COVID-19 and non-alcoholic fatty liver disease
Manuscript Source	Invited Manuscript
All Author List	Francesco Bellanti and Gianluigi Vendemiale
Funding Agency and Grant Number
Corresponding Author	Francesco Bellanti, MD, PhD, Doctor, Doctor, Research Associate, Teaching Assistant, Department of Medical and Surgical Sciences, University of Foggia, Viale Pinto, 1, Foggia 71122, Italy. francesco.bellanti@unifg.it
Key Words	Non-alcoholic fatty liver disease; Metabolic-associated fatty liver disease; COVID-19; SARS-CoV-2; Liver injury; Immune dysregulation
Core Tip	Non-alcoholic fatty liver disease (NAFLD) is the most widespread hepatic disorder. Recently re-named as metabolic-associated fatty liver disease (MAFLD), it has been lately pointed out as a predisposing factor for severe coronavirus disease 2019 (COVID-19). We herein discuss the epidemiology and possible underlying pathways predisposing severe COVID-19 in NAFLD/MAFLD patients.
Publish Date	2021-09-22 08:09
Citation	Bellanti F, Vendemiale G. COVID-19 and non-alcoholic fatty liver disease. World J Hepatol 2021; 13(9): 969-978
URL	https://www.wjgnet.com/1948-5182/full/v13/i9/969.htm
DOI	https://dx.doi.org/10.4254/wjh.v13.i9.969

Full Article (PDF)	WJH-13-969.pdf
Full Article (Word)	WJH-13-969.docx
Manuscript File	68617-Review-FilipodiaCL.docx
Answering Reviewers	68617-Answering reviewers.pdf
Audio Core Tip	68617-Audio core tip.m4a
Conflict-of-Interest Disclosure Form	68617-Conflict-of-interest statement.pdf
Copyright License Agreement	68617-Copyright license agreement.pdf
Non-Native Speakers of English Editing Certificate	68617-Language certificate.pdf
Peer-review Report	68617-Peer-review(s).pdf
Scientific Misconduct Check	68617-Bing-Wang JJ-2.png
Scientific Misconduct Check	68617-Scientific misconduct check.pdf
Scientific Editor Work List	68617-Scientific editor work list.pdf
CrossCheck Report	68617-CrossCheck report.pdf